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Periodontitis is an inflammatory disease involving the supporting structures of the 
dentition.  Many studies have shown that there is a relationship between periodontal 
disease, the presence of pro-inflammatory cytokines, and systemic disease such as 
cardiovascular disease and diabetes mellitus.  The purpose of this study was to measure 
serum Interleukin-6 levels in generalized and localized aggressive periodontitis and non-
periodontitis patients and look for relationships with measures of disease severity.  We 
also examined variables known to have a relationship with IL-6.  A total of 172 subjects, 
comprising three periodontal subgroups, non-periodontitis (NP=61), generalized  
 aggressive periodontitis (GAP=77), and localized aggressive periodontitis (LAP= 34), 
had serum samples evaluated for IL-6 levels using a highly sensitive ELISA test.  The IL-
6 levels were compared with clinical and demographic data including age, race, gender, 
number of teeth, probing depth, attachment loss, bleeding index, plaque index, gingival 
index, cotinine levels, smoking status, and CRP levels.  Using multiple regression 
analysis, smoking status (p=0.0015) was the only variable found to have a significant 
relationship with IL-6 levels for all three groups.   
 Introduction 
 
 
 
 
Periodontitis is an inflammatory disease involving the supporting structures of the 
dentition including the cementum, bone, and periodontal ligament.  The initial 
presentation of the disease is localized to the gingival sulcus and coronal connective 
tissue.  However, the disease process, if allowed to progress, can result in periodontal 
attachment loss and bone destruction.1 Approximately 50% of the United States 
population has gingivitis around three or four teeth at any given time and 35% have 
periodontitis defined by the presence of one or more teeth with attachment loss and 
probing depth ≥ 3mm.2 
Juvenile periodontitis, which we now classify under aggressive periodontitis, is a 
term which is defined by Baer3 as a disease of the periodontium occurring in an otherwise 
healthy adolescent which is characterized by rapid loss of alveolar bone about more than 
one tooth of the permanent dentition.  There are two basic forms in which it occurs.  In 
the localized form, the only teeth affected are the first molars and incisors.  In the 
generalized form, it may affect most of the dentition.4  According to Baer, the amount of 
destruction is not related to the local irritants or amount of plaque present.3   However, 
Burmeister et al.5 refute this idea and have reported a positive correlation between plaque 
present and the degree of destruction seen in aggressive cases. Using 
 the 1991 National Institute of Dental Research national survey, Löe and Brown reported 
that the prevalence of localized juvenile periodontitis was 0.53% and generalized juvenile 
periodontitis was 0.13%.  Males were slightly more likely to have the localized form of 
the disease, with blacks more likely than whites to have either form.6  
Both chronic and aggressive forms of periodontitis are characterized by 
inflammation.  Phagocytic cells are recruited to the site of infection through the release of 
cytokines and other inflammatory mediators.  These cytokines include interleukin-1 (IL-
1), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-12 (IL-12), and tumor necrosis 
factor α (TNF-α).  All of these mediators have important local and systemic effects. 
The inflammation and destruction which comprise periodontal disease result from 
the host immune response to bacterial challenge.  Bacteria and bacterial components such 
as lipopolysaccharide (LPS) result in the production of inflammatory mediators, such as 
cytokines, by activated macrophages and fibroblasts present in periodontitis lesions.7,8  
Several bacteria including Actinobaccilus actinomycetemcomitans (Aa) and 
Camphylobacter rectus (Cr) have been shown to amplify human host inflammatory 
reactions mediated by pro-inflammatory cytokines, including IL-6 and IL-8.9  There have 
been several other pro-inflammatory cytokines implicated in the immunopathology of 
periodontitis, with the most convincing evidence for destruction of the periodontium for 
Interleukin-1 beta (IL-1β),10,11,12,13 and TNF-α.14,15,16  Elevated levels of pro-
inflammatory cytokines have been found in inflamed periodontal tissues and 
systemically.17,18,19  Due to the presence of bacterial plaque and cytokine activation, an 
inflammatory response occurs which may have global consequences throughout the body.  
 The cytokines IL-1, IL-6, and TNF-α are key mediators in inflammation.  These 
cytokines cause systemic effects such as increased body temperature, neutrophil 
mobilization, and increased lymphocyte activation.20  They are of particular importance 
due to their role in the acute-phase response.20  This response involves the release of 
proteins by hepatocytes such as C-reactive protein (CRP) and mannan-binding lectin.21  
These two proteins are capable of initiating complement activation and opsonization of 
target bacteria.20  Thus, the presence of molecules such as IL-1, IL-6, TNF-α, and CRP 
has become a marker of inflammation and the initiation of host defense mechanisms.  
Cytokines play an important role in the pathophysiology of chronic inflammatory 
diseases, including periodontitis.  IL-6 in particular is a major mediator of the host 
response to tissue injury, infection, and bone resorption. 20  IL-6 is a critical component of 
the acute-phase response because it triggers the release of CRP which is involved in 
immune response and pro-inflammatory host reactions. 20 
The role of IL-6 and periodontal bacteria, specifically, has been examined.  One 
such study by Kesavalu et al.22 looked at murine tissue expression of pro-inflammatory 
cytokines TNF-alpha, IL-6, and IL-1 beta in response to challenge with periodontal 
pathogens such as Porphyromonas gingivalis (Pg) and Actinobacillus 
actimomycetemcomitans (Aa).  Results of the study showed that both Pg and Aa elicited 
elicited expression of all three cytokines with Pg being more potent than Aa in inducing 
cytokine expression.  In another study by Nakamura et al.,23 blood samples from seven 
healthy subjects were treated with Aa lipopolysaccharide (LPS) and tested for IL-6 and 
IL-1 beta expression.  Blood cells pre-treated with Aa LPS showed increased production 
of IL-1 beta and IL-6 compared to non-LPS pre-treated cells.  Also, further analysis 
 showed that the monocyte fraction of the blood was mostly responsible for the increased 
cytokine production seen.  Collectively, this data shows that tissues do respond to 
bacteria and their byproducts by mounting an inflammatory reaction which includes 
activation of inflammatory cells and production of inflammatory cytokines. 
Barthold et al.18 examined IL-6 production by human gingival fibroblasts using 
immunohistochemistry. In the study, they were able to localize IL-6 production within 
the connective tissue and lower portions of gingival epithelium. They found that areas of 
inflammation showed a much more intense staining for IL-6 and concluded that there 
may be an association between this inflammatory cytokine and periodontal disease. In 
another study by Chen et al.,24 levels of IL-6 and IL-1 beta were examined in both the 
gingival tissue and serum of patients with periodontal disease and of periodontally 
healthy patients. The levels of both cytokines were measured by ELISA. A positively 
significant relationship was found between levels of IL-6 and clinical assessments of 
periodontal destruction. IL-6 levels were found to increase in tissues of periodontitis 
patients.  
Many studies have shown a correlation between periodontitis and systemic 
disease involving cytokines such as IL-6 as a shared mechanism of 
inflammation.25,26,27,28,29,30,31,32,33  In one such study, gingival crevicular fluid (GCF) 
levels of IL-6 were determined in patients with type II Diabetes Mellitus (T2DM) with 
periodontitis, adult periodontitis, and healthy controls.  The mean GCF IL-6 levels were 
highest in T2DM patients with periodontitis, followed by the adult periodontitis patients 
with the healthy controls having the lowest levels.25  These findings suggest that GCF IL-
6 levels were significantly higher in areas of inflammation and periodontal destruction.  
 Studies by Offenbacher et al.26 have shown a relationship between periodontal 
disease and pre-term low birth weight (PLBW) infants.  The inflammatory mediators that 
occur in periodontal disease also play a significant role in the initiation of labor and 
provide a plausible mechanism which may link the two together.  Lopez et al.27 
investigated whether the maintenance of a mothers’ periodontal health after 28 weeks 
gestation reduced the risk of PLBW infants.  They found that the incidence of PLBW was 
2.5% in periodontally healthy women, and 8.6% in women with periodontal disease 
(p=0.0004).  
In the Physician’s Health Study, Ridker et al.28 found elevated levels of IL-6 in 
apparently healthy males predicted up to a 2.3-fold increase in myocardial infarction over 
6 years.  Among these men, the number of risk factors at baseline was correlated with the 
plasma concentration of IL-6.  In another study, Ridker et al. 29 also reported that baseline 
IL-6 levels have been found to predict cardiovascular events in the Women’s Health 
Study.  Bermudez et al. 30 discuss several clinical cardiovascular risk factors which are 
related to circulating plasma levels of IL-6 and CRP in women.  Specifically, age, BMI, 
smoking status, systolic blood pressure, alcohol use, presence of diabetes, and exercise 
frequency are all independent correlates of circulating plasma concentrations of IL-6.   
Ciancio31 reports many risk factors which are associated with both periodontal 
disease and cardiovascular disease including age, smoking, diabetes, obesity, stress and 
diet.  According to Ciancio practitioners must consider these shared risk factors in 
diagnosing and treating periodontal disease.  In addition to these associations, a pathway 
relating oral conditions with cardiovascular disease is discussed by Joshipura et al.32 
whereby periodontal disease can lead to increased tooth loss and inflammation followed 
 by dietary changes, stress, vascular injury, bacteremia and possible coronary vascular 
disease outcomes such as endocarditis, stroke and coronary heart disease.  Iacopino and 
Cutler33 show a linkage between infection and hyperlipidemia.  In this model chronic 
periodontitis and/or acute infection cause bacteremia and endotoxemia which leads to 
increased serum pro-inflammatory cytokine production.  The cytokines then cause 
enhanced lipogenesis and reduced lipid clearance with a resultant increase in free fatty 
acids, LDL, and triglycerides.  This model is cyclic in nature and as lipid levels are 
further elevated, periodontitis is exacerbated leading to worse inflammation and lipid 
levels. 
Although an exact causal mechanism has not yet been determined, the risk factors 
and associations between periodontal disease and systemic disease are strong.  The key 
underlying shared characteristic is inflammation.  Based on the biology of inflammation 
we know that pro-inflammatory cytokines are major mediators involved in inflammatory 
changes throughout the human body.  IL-6 has been found in inflamed periodontal tissues 
at increased levels compared to healthy tissues.  Several studies have demonstrated local 
increases in IL-6 levels in gingival crevicular fluid and gingival tissues in response to 
periodontitis.18,24,25,34,35,36  However, at present, there is no published data which 
correlates serum levels of IL-6 with periodontal disease and oral inflammation.  Thus, 
there is a need for studies examining the relationship between systemic IL-6 serum 
concentrations and periodontitis as well as studies on the effect of periodontal therapy on 
serum IL-6 concentrations.  This information is of particular importance due to the 
potential therapeutic implications and close relationship between periodontal disease and 
systemic disease. 
 HYPOTHESIS: IL-6 levels are elevated in the serum of certain patient groups 
with periodontal disease.  There is a link between inflammatory systemic conditions and 
the periodontal oral inflammation.  Periodontal therapy could potentially help to alleviate 
and ameliorate certain inflammatory systemic diseases and their symptoms.  The purpose 
of this study is to measure IL-6 serum levels in generalized and localized aggressive 
periodontitis patient populations and healthy controls and determine if there is a 
relationship between this variable and measures of periodontal health.  We also will 
examine additional variables known to relate to IL-6 levels.  
 Materials and Methods 
 
 
 
 
Patient Selection and Clinical Examination 
 
All subjects were taken from the VCU Clinical Research Center for Periodontal Disease 
Database.  The database included patients referred to the center and patients identified 
from the dental population at VCU School of Dentistry.  All patients signed an informed 
consent form approved by VCU Committee on the Conduct of Human Research.  A total 
of 172 subjects had a medical history obtained by questionnaire and interview, complete 
dental exam, and matching serum samples with clinical exam.  Complete exams consisted 
of suppuration index, plaque index (APLI),37 gingival index (AGI),38 pocket depth (PKT 
Avg), bleeding index (ABI), attachment loss measurements (Aloss), and tooth mobility.  
Missing and deciduous teeth were also recorded. Smoking status, cotinine levels, CRP 
levels were also measured.  Clinical exam was measured at 4 sites per tooth (mesio-
buccal, buccal, distal-buccal, and lingual) with a Hu-Friedy color-coded probe (PCP 12).  
Diabetic subjects and subjects with reported arthritis were eliminated from the database.  
All examiners performing exams were calibrated to verify examiner reliability.39 
 
 
 
 Subject Groups 
Aggressive Periodontitis.  Encompasses distinct types of periodontitis that affect people 
who, in most cases, otherwise appear healthy.  It tends to have a familial aggregation and 
there is a rapid rate of disease progression.  Aggressive periodontitis occurs in 
generalized and localized forms. 
Generalized Aggressive Periodontitis- A total of 77 subjects showing a 
generalized pattern of severe periodontal destruction with attachment loss of at 
least 5 mm on eight or more teeth, at least 3 of which are not first molars and 
incisors.  Subjects ranged in age from 12 to 67 years. 
 
Localized Aggressive Periodontitis- A total of 34 subjects. Clinical attachment 
loss pattern—must have at least 4 mm attachment loss (Aloss) on at least 2 
permanent first molars and incisors (at least one molar must be affected) and no 
more than 2 teeth, which are not first molars or incisors that are affected by 5 mm 
AL or more.  Subjects ranged in age from 8 to 46 years. 
 
Non-Periodontitis (NP).  A total of 61 subjects with no evidence of attachment loss at 
more than one site, except for recession on the buccal of anterior teeth, or pockets greater 
than 3 mm.  That is, no detectable periodontitis; healthy periodontium.  Gingival 
inflammation may be present in variable degrees of severity. Subjects ranged in age from 
6 to 50 years of age. 
 
 
 IL-6 Assay 
96-well microtiter plates were used which were coated with antibody for human IL-6.  
Standard serial dilutions of recombinant human IL-6 were prepared with a standard 
diluent 0.1% (w/v) sodium azide.  IL-6 levels ranged from 0.63-20 pg/ml. 100µl of 
standard diluent was loaded into designated wells and 100 µl of sample was loaded into 
the appropriate wells on the 96 well microtiter plates.  Plates were then covered and 
stored for 2 hours at room temperature (20-25°C) with continuous shaking.  After this 
incubation period, each well was aspirated and washed thoroughly with wash buffer for a 
total of four washes.  Complete liquid removal was assured after each wash step.  After 
the wash cycles, 100 of biotinylated antibody reagent was pipetted into all wells.  Plates 
were again covered and incubated for 30 minutes at room temperature (20-25°C) with 
continuous shaking.  The wash and aspiration cycle was again repeated four times as 
described above.  Next 100 µl of Amdex amplification reagent was added to all wells.  
Plates were covered with new adhesive strips and and incubated for 30 minutes at room 
temperature (20-25°C) with continuous shaking.  The wash and aspiration cycle was 
again repeated four times as described above.  Finally 100 µl of TMB substrate was 
added to each well and incubated for 30 minutes at room temperature (20-25°C) with 
continuous shaking.  Plates were not covered during this step.  Following the 30 minute 
incubation, 100 µl of stop solution was added to each well.  Optical density was then 
determined for each well within 30 minutes using a spectrophotometer set to 450nm.  The 
duplicate readings for each standard and sample were averaged and the zero standard 
optical density was subtracted from each value. 
 
 Statistical Analysis 
One way ANOVA and bivariate analysis were used to calculate the significance of IL-6 
levels against various continuous and dichotomous variables including race, sex, number 
of teeth, pocket depth (PKT Avg), attachment loss (Aloss), plaque index (APLI), gingival 
index (AGI), bleeding index (ABI), reported smoking status, cotinine levels, and CRP 
levels within each subject group.  Multiple regression was used to calculate significance 
of IL-6 levels against these variables for all three subject groups combined.  A 
significance level of 0.05 was used.  Stepwise regression was then performed using 
variables which approached significance with p< 0.2.  
 
 
 Results 
 
 
 
 
Patient demographics and parameter means are given in Tables 1 and 2. Table 1 
shows mean values and standard errors of the continuous variables measured for each 
subject group.  Table 2 shows percentages for dichotomous variables measured for each 
subject group.  
We compared the IL-6 levels in each patient group to the variables found in 
Tables 1 and 2 (Table 3).  In Table 3, a statistically significant correlation was found 
between IL-6 levels and smoking status within the LAP patient group (p<0.0001). No 
other significant differences were found. 
We then combined the data for all 3 groups and examined the relationship 
between IL-6 and the variables in Tables 1 and 2 including attachment loss and 
periodontal classification (Table 4).  Non-smokers had significantly lower IL-6 levels 
(odds ratio= -3.11, p= 0.0024) and smokers had significantly higher IL-6 levels (odds 
ratio= 3.26, p= 0.0015) (Table 4).  A trend was noted between LAP periodontal status 
and IL-6 levels (odds ratio=1.88, p=0.0627) (Table 4).  No significant results were noted. 
Stepwise regression analysis was used for factors which approached significance 
using p< 0.2. The three variables tested were LAP status, smoking, and plaque index.  
Results showed that smokers again had significantly elevated IL-6 levels (p< 0.0001). 
 LAP patients showed increased IL-6 levels, but results were still not significant 
(p=0.0587).  Plaque index was not significant (p=0.1302). 
  
 
 
 
Table 1 
 
Mean Values of Continuous Variables Measured for Patient Subgroups 
 
 
 
 LAP ±Std error GAP ±Std error NP ±Std error 
Age 22.7  31.3  31.0  
Number of Teeth 26.970588 ±0.415 24.571429 ±0.640 27.508197 ±0.352 
PKT Avg 2.6369407 ±0.095 3.437879 ±0.101 2.0684114 ±0.256 
Aloss 0.6489857 ±0.075 2.5871881 ±0.180 0.2468588 ±0.036 
APLI 0.8624218 ±0.084 1.2406649 ±0.057 0.5018255 ±0.055 
AGI 1.173042 ±0.064 1.3570198 ±0.048 0.6055005 ±0.047 
ABI 0.3527414 ±0.038 0.4450448 ±0.027 0.1833749 ±0.025 
Cotinine 64.909524  ±26.597 202.22466  ±34.115 35.3785571  ±20.694 
IL-6 mean 3.5356176 ±2.015 1.258987 ±0.252 2.2888852 ±1.071 
CRP mean 3.6125882 ±0.638 3.7772987 ±0.390 1.5823607 ±0.270 
 
 
 
 
Table 2 
 
Dichotomous Variables Measured for Patient Subgroups 
 
 
 
 
  LAP GAP NP 
Race Black 0.76471 0.62338 0.22951 
 White 0.20588 0.37662 0.77049 
Sex Male 0.41176 0.33766 0.52459 
 Female 0.58824 0.66234 0.47541 
Smoker Yes 0.32353 0.62338 0.52459 
 No 0.67647 0.37662 0.47541 
 
  
 
 
 
Table 3     
 
IL-6 Levels of Patient Subgroups Based on Variables Measured 
 
 
 
 
 
 
P-Values 
 LAP GAP NP 
Race 0.5072 0.3416 0.5217 
Sex 0.8914 0.2048 0.9591 
Number of Teeth 0.5158 0.3443 0.8787 
PKT Avg 0.6975 0.2397 0.7560 
Aloss 0.5770 0.6487 0.4245 
APLI 0.1127 0.1284 0.9062 
AGI 0.5825 0.9129 0.5224 
ABI 0.8210 0.5060 0.5375 
Cotinine 0.6725 0.4536 0.6687 
Smoking Status <0.0001* 0.4584 0.1190 
CRP 0.1000 0.7714 0.3630 
 
   *Statistically significant P values obtained by bivariate analysis
  
 
 
 
    Table 4   
 
Significance of Variables on IL-6 Levels-Comparisons Across 
     All Patient Subgroups 
 
 
 
 
 t ratio Prob>t  
Class (LAP) 1.88 0.0627 
Class (GAP) -0.18 0.8600 
Class (NP) -0.39 0.6958 
Race (Black) -0.32 0.7469 
Sex (F) -0.42 0.6759 
Number of Teeth -0.36 0.7214 
PKT Avg 0.50 0.6172 
Aloss -0.35 0.7308 
APLI -1.58 0.1173 
AGI 0.58 0.5614 
ABI -0.04 0.9700 
COTININE -0.21 0.8377 
Smoker (Y) 3.26 0.0015* 
Smoker (N) -3.11 0.0024** 
CRP mean -0.01 0.9941 
 
    *statistically significant increase in IL-6 levels 
   **statistically significant decrease in IL-6 levels 
  
 
 
 
Discussion 
 
 
 
 
In this study we examined the relationship of IL-6 and measures of periodontal 
disease in LAP and GAP patients.  We also examined variables known to relate to IL-6, 
including CRP.  The only variable which was significantly related to IL-6 levels was 
smoking.  It is not surprising that smoking was found to be significantly correlated to 
increased IL-6 levels.  Several studies have also shown the mechanisms by which 
smoking may affect the periodontium including PMN chemotaxis problems, increased 
proportions of harmful periodontal microflora, increased bone andattachment loss, and 
poor wound healing.40,41,42,43,44,45,46,47,48  Tomar et al.49 researched the NHANES III 
database and found that current smokers were about 2-3 times as likely as non-smokers to 
have periodontitis.  The odds ratios ranged from 2.79 for those who smoked < 10 
cigarettes/day to 5.88 for those who smoke >30/day.  They also calculated that smoking 
cigarettes may be responsible for over 50% of the cases of periodontitis among adults in 
the United States.  Grossi et al.46,47 assessed risk indicators for alveolar bone loss and 
attachment loss.  They found that smokers had greater odds ratios than non-smokers for 
bone loss ranging from 3.25 for light smokers to 7.28 for heavy smokers and attachment 
loss ranging from 2.05 for light smokers to 4.75 for heavy smokers.  These odds ratios 
are similar to the odds ratio we found between smoking and IL-6 of 3.26.   
 Giannopoulou et al.36 looked at the effects of smoking and inflammation on 
gingival crevicular fluid cytokine levels in 40 patients with aggressive and chronic 
periodontitis and 20 patients with gingivitis compared to 20 healthy controls.  They found 
that IL-6, IL-8 and IL-1 beta levels were significantly elevated in peridontally diseased 
subjects compared to healthy controls.  They also reported that IL-4, IL-6, IL-8 and IL-1 
beta were all positively correlated with probing depths. IL-4, IL-6 and IL-8 were found to 
be correlated to smoking.  Therefore, we can see the relationship between smoking, 
inflammation, and periodontal destruction as evidence and support for our findings. 
We noted that amongst the three subject groups, LAP status showed an increased 
odds ratio (t ratio=1.88, p=0.0627) of elevated IL-6 levels.  The literature shows a 
relationship between inflammation and clinical parameters of periodontitis such as 
bleeding and increased probing depths which may explain this correlation.50,51,52  Studies 
by Caton et al.52,53 and Davenport et al.54 have shown that bleeding is indicative of 
histologic inflammatory changes occurring within the tissues.  Bleeding on probing along 
with suppuration or increased probing depths can be predictive of future attachment 
loss.50,51  A 2002 VCU Master’s thesis project by Fernandez55 also examined the 
relationship between periodontal disease (local inflammation) and cardiovascular disease 
(systemic inflammation) using the NHANES III database.  Results of the project showed 
that gingival bleeding was significantly related to a history of non-fatal heart attack with 
an odds ratio of 1.95.  Discussion related bleeding to periodontal inflammation and the 
possible role of pro-inflammatory cytokines in leading to further systemic inflammation.  
A study by Willerhausen et al. 56 shows that there is a correlation between inflammatory 
periodontal disease and cardiovascular disease.  They found that mean bleeding index 
 was significantly higher in coronary heart disease patients compared to healthy controls.  
Based on these previous studies we can see a possible relationship between clinical 
periodontitis and inflammation and would expect to see increased pro-inflammatory 
cytokines such as IL-6. 
IL-6 is part of the acute phase response and causes CRP to be released by 
hepatocytes, which is then involved in initiating complement activation and opsonization 
of target bacteria. 20  We noted a correlation between LAP status and IL-6 cytokine levels.  
However, results did not show any increase or significance in IL-6 levels when measured 
against CRP in any of the subgroups.  D’Aiuto et al. 57 conducted a pilot study on 94 
subjects and assessed serum CRP and IL-6 levels at baseline and at 2 and 6 months 
following non-surgical periodontal therapy. They found significant reductions in CRP 
and IL-6 serum levels along with improvement in all clinical periodontal parameters with 
therapy.   In another related study, Loos et al. 58 looked at CRP and IL-6 levels in 
periodontitis patients. They examined 53 localized periodontitis patients, 54 generalized 
periodontitis patients and 43 healthy controls and found significantly higher mean levels 
of CRP and IL-6 in periodontitis patients compared to controls.  They also found that 
CRP and IL-6 correlated with each other, and both correlated with the number of 
neutrophils in the peripheral blood samples of the periodontitis patients.  We would 
expect to see a correlation between IL-6 and CRP in the subjects.  However, in our study, 
we did not note such a correlation.   
It is possible that the reason we failed to find relationships for IL-6 reported by 
others was due to degradation or denaturation of the IL-6 in the samples used for our 
experiments.  In our study, the serum samples were obtained over the last 20 years and 
 some have been repeatedly thawed and frozen during ongoing projects.  We suspect that 
there may have been a problem with the stability of IL-6 in the sample serum.  Kenis et 
al. 59 examined the stability of IL-6 in human serum under varying conditions. They 
looked at the concentration of serum IL-6 stored at 4ºC, 20ºC, 30ºC, and 40ºC for 1 to 21 
days compared to triplicate samples of the same person frozen at -20ºC.  They found that 
recovery of IL-6 did not decrease for up to 21 days at 4ºC, 20ºC or 30ºC and only 
decreased after 21 days at 40ºC.  They found that the concentration of IL-6 did not 
change when incubated at 4ºC or 20ºC for up to 4 days before centrifugation.  They also 
found that up to four repeated freeze-thaw cycles did not influence recovery of IL-6 in 
their study.  These results do not corroborate those from Flower et al. 60 who found that 
IL-6 concentrations were affected by various treatments prior to experimental use.  
Serum samples were obtained from healthy subjects and examined for IL-6 levels under 
many conditions: (i) standing for 1, 2, 4, or 6 h prior to, or after separation, before 
freezing at -70 degrees C; (ii) taken into tubes with different anticoagulants or no 
anticoagulant, separated and frozen; and (iii) separated, and repeatedly freeze-thawed for 
up to six cycles prior to assay.  Results showed that storage conditions can significantly 
alter the concentrations of the molecules and need to be standardized.  Also, the type of 
anticoagulant used and the number of freezing cycles may alter the concentration of 
cytokines and should be considered when studies are being conducted.  Another study by 
Thavasu et al. 61 looked at blood cytokine levels of many cytokines including IL-6 under 
different anticoagulant, processing, and storage conditions.  The study showed that the 
stability and recovery of the cytokines was affected by the varying study parameters.  
Handling methods did influence cytokine levels.  The recovery of IL-6 from serum 
 samples was found to be consistently lower than the amount recovered from plasma 
samples.  Therefore, the properties and concentrations of the cytokine in the samples may 
have been altered by the treatment of the samples prior to use.   
Interestingly, Sothern et al.62,63 conducted two studies which examined the 
circadian characteristics of IL-6 in blood and urine samples of clinically healthy men.  
Because most human biologic activities and functions are governed by circadian rhythms, 
this group tested the activity of IL-6 during various daytime and nighttime hours.  They 
found that average IL-6 values ranged from 1.66 to 5.38 pg/ml, with the lowest to highest 
values within 24 hours ranging from 1.20 to 7.58 pg/ml between subjects.  On average, 
values were greater than the mean throughout the night, with a peak at 01:00 hours and 
less than the mean throughout the day, with the lowest value at 10:00 hours.  The 
opposite trend was found for urine IL-6 levels with the highest values found during the 
day and the lowest values found at night.  A significant time effect was found by 
ANOVA.  They suggested that endogenous IL-6 levels may be significantly altered by 
their large day-night variations and the type of fluid collected.  In our study, subjects 
were seen in the clinics during the daytime, during office hours only. Therefore, it is 
possible that IL-6 serum concentrations were affected by collection times. 
In future studies, we will collect samples and use them within a given time period.  
Storage and processing protocols must be carefully laid out ahead of time.  We will also 
avoid repeated freezing and thawing of samples for use.  Samples should be aliquoted in 
small amounts so that fresh sample tubes could be used for each experiment and 
contamination would be avoided.  We will thus possibly prevent some product loss due to 
improper handling conditions.  It would also be interesting to investigate the relationship 
 between collection time and serum IL-6 concentrations in our patient population.  Finally, 
in light of these past studies, it would seem wise to standardize collection times to certain 
parts of the day in order to prevent bias in the results. 
We hypothesized that serum IL-6 concentrations, like gingival tissue 
concentrations,18,24 would be increased and directly related to periodontal breakdown and 
disease in our patient population.  The study by Loos et al.58 previously discussed 
examined levels IL-6 and CRP in the peripheral blood of periodontitis patients.  They 
found that CRP, IL-6 and neutrophil levels were elevated in periodontitis patients.  The 
elevated pro-inflammatory markers may be related to the inflammation seen in 
cardiovascular disease and may lead to an increased risk for cardiac sequellae such as 
development of atherosclerotic lesions in this patient population.  If there is indeed a 
relationship between systemic inflammation, cardiovascular disease, and periodontitis, 
then therapeutic measures aimed at reducing periodontal inflammation are warranted.  In 
the future we would like to examine the relationship between periodontal therapy and 
serum IL-6 concentrations and hope to see that therapy will help in reducing the amount 
of this pro-inflammatory cytokine within the patient’s system.  Perhaps we can then 
explain a causal relationship amongst systemic inflammation, cardiovascular disease, and 
periodontal disease. 
Some recent studies have investigated different avenues of therapy for combating 
periodontal inflammation and perhaps subsequent systemic inflammation.  In a study by 
Tipton et al.,64 the role of cyclooxygenase-2 (COX-2) inhibitors in periodontal therapy 
was examined.  Gingival fibroblasts were cultured in medium with IL-1 beta, with or 
without COX-2 inhibitors.  Results showed that COX-2 inhibitors caused dose-dependent 
 decreases in PGE-2 and IL-6 production by IL-1 beta stimulated gingival fibroblast and 
may be useful in controlling inflammation in these patients.  Thus, a link is shown 
between systemic therapy and treatment of periodontitis.  In a study last year, Takashiba 
et al.65 discussed a possible role for anti-cytokine therapy, such as anti-IL-6 antibodies, in 
combating periodontal inflammation.  If a direct relationship is found among serum 
levels of IL-6 and other inflammatory cytokines and periodontitis on a systemic level 
then systemic therapy such as vaccinations may be possible and warranted.   
In this study, a significant correlation was found between serum IL-6 levels and 
smoking status.  Also, a trend was noted between LAP periodontal status and IL-6 levels.  
Our future studies will aim to repeat this work with standardized handeling of serum 
samples as described above. We will also examine the relationship of periodontal therapy 
and IL-6 levels in patients with chronic and aggressive periodontitis. 
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